Navigation Links
New approach for attacking lupus identified
Date:12/17/2007

NEW YORK CITY, Dec. 16, 2007 Investigators at Hospital for Special Surgery have identified two new targets for drugs aimed at controlling lupus. If companies are able to develop drugs that hone in on these targets, patients may be able to control their disease with few side effects.

The study identifies very good therapeutic targets, and what needs to be done is identify better candidate drugs, said Lionel Ivashkiv, M.D., director of Basic Research at Hospital for Special Surgery in New York City. He led the study, which was published online in Nature Immunology on December 16 and will appear in print in February.

Because abnormally high levels of interferon-alpha can lead to lupus, researchers have developed drugs that block interferon. These drugs, however, have immunosuppressive side effects that can leave patients vulnerable to various illnesses and infections, some of which can be deadly. Currently, these drugs are being tested in clinical trials. If researchers are able to develop drugs for the newly identified drug targets, patients may be able to avoid these immunosuppressive effects.

Interferons have two major functions. First, they protect against viruses and second, they regulate immune responses, strengthening immune responses and playing a role in autoimmunity. Different proteins, called STATs, mediate the two functions of IFN. STAT1 mediates the autoimmune and inflammatory functions, and STAT2 mediates the virus protection function. What we were interested in understanding is how you can regulate the balance between activating the inflammatory effects and the antiviral effects, Dr. Ivashkiv said. We thought if we could control the functions of the interferons, that would lead to new therapeutic approaches where you could block specifically some of their functions, but not others.

The investigators discovered that calcium specifically increases activation of STAT1 by interferons, and thus turned their attention to calcium. The researchers tested whether two kinase enzymes in the calcium-signaling pathway, CAMK and Pyk2, could be manipulated to control STAT1. In studies involving mice, the investigators showed that blocking these calcium-signaling pathways with a drug called KN-93 regulated the amount of STAT1, but not STAT2 activation.

What we found was that these kinases that are regulated by calcium actually regulate the strength of activation of STAT1 by the interferons, but they do not regulate the strength of activation of STAT2, said Dr. Ivashkiv. The idea was if you block these signaling pathways, would you block the STAT1 part, which controls the inflammatory/deleterious effects and preserve the antiviral part. We tested that in an animal model of lupus and we were able to show, in vivo, that you can suppress STAT1 activation by inhibiting the calcium-dependent kinases.

The researchers say that their work has identified a new therapeutic approach for attacking lupus. What the companies are trying to develop are, basically, antibodies against the interferons. The concern there is that if you block the interferon completely, patients may become very immunosuppressed and unable to handle viral infections, Dr. Ivashkiv said. Our idea is that if you block these calcium pathways, you could block the deleterious effects of the interferon, but maintain the antiviral effects.

Lupus is an autoimmune disease that can affect various parts of the body, including the skin, joints, heart, lungs, blood, kidneys and brain. Inflammation, considered the primary feature of lupus, is characterized by pain, heat, redness, swelling and loss of function. In most people, the disease affects only a few organs and symptoms are mild, but in others, the disease can cause serious and even life-threatening problems. According to the Lupus Foundation of America, an estimated 16,000 Americans develop lupus each year.


'/>"/>

Contact: Phyllis Fisher
fisherp@hss.edu
212-606-1724
Hospital for Special Surgery
Source:Eurekalert

Related biology news :

1. Layered approach may yield stronger, more successful bone implants
2. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
3. Book on weeds and invasive plants discusses how to manage them using ecological approaches
4. New thoracic imaging approach can pinpoint underlying venous problems
5. Gold nanorods shed light on new approach to fighting cancer
6. Deadlines for 2007 National Soybean Rust Symposium fast approaching
7. New approach builds better proteins inside a computer
8. Raydiance collaborates with Rutgers, MTF to develop innovative tissue processing approaches
9. Study identifies genetic risk factor for rheumatoid arthritis, lupus
10. Lupus Research Institute strategy delivers $30 million in national funding
11. Lupus gene finding prompts call for more DNA samples
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... area for financial services, but it also plays a fundamental ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):
(Date:5/3/2016)... ... May 03, 2016 , ... Wearable Tech ... driven conferences, will take place on June 7-8, 2016, at the New York Academy ... on incorporating technology -- including AR/VR, machine learning, apps, robotics and AI -- throughout ...
(Date:5/2/2016)... Q BioMed Inc. (QBIO), a ... Research Inc. will be attending the Association for Research ... May 1-5, 2016 in Seattle Washington ... vendors and research partners. The meeting provides organizations the ... collaborative opportunities for the MAN-01 program for treatment of ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... pain medicine, is excited to announce the launch of the Proove Health ... studies, volunteerism, and education to promote the use of personalized medicine for tackling ...
(Date:4/29/2016)... ... April 29, 2016 , ... Intelligent Implant Systems announced today ... via 510(k) for sale in the United States. These components expand the capabilities ... With one-level sales beginning in October of 2015, the company has seen significant ...
Breaking Biology Technology: